8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Jan 26, 2022)

Filed January 26, 2022For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) has filed an 8-K report on January 26, 2022, to announce its fourth quarter 2021 financial results. The press release furnishing the detailed results is incorporated by reference, offering investors insight into the company's performance for the period ending December 31, 2021. While specific figures are not detailed within the 8-K itself, the filing indicates that the press release contains crucial information regarding the company's operational and financial condition for the quarter. Investors should refer to the furnished press release (Exhibit 99.1) for quantitative data and management commentary on sales, profitability, and any forward-looking guidance. This report serves as a notification of the release of these results, which are critical for assessing the company's recent trajectory and future outlook. Key areas to scrutinize in the accompanying press release will likely include sales performance across Edwards' various product segments (such as Transcatheter Heart Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, and Critical Care), earnings per share (EPS), and any updates on strategic initiatives or clinical trial progress. Understanding these financial outcomes is paramount for making informed investment decisions regarding Edwards Lifesciences.

Key Highlights

  • 1Edwards Lifesciences filed an 8-K on January 26, 2022, announcing Q4 2021 financial results.
  • 2The press release detailing the Q4 2021 financial results is furnished as Exhibit 99.1 and incorporated by reference.
  • 3Investors should consult Exhibit 99.1 for specific financial data and operational performance.
  • 4The filing pertains to the company's financial condition and results of operations for the fourth quarter of 2021.
  • 5This report signals the availability of key performance indicators and management commentary for the period.
  • 6The information is furnished and not deemed 'filed' for purposes of the Securities Exchange Act of 1934.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide access to Edwards Lifesciences' financial results for the fourth quarter of 2021, as detailed in a press release furnished as an exhibit.

The specific financial numbers, including sales, profitability, and earnings per share for the fourth quarter of 2021, can be found in the press release dated January 26, 2022, which is included as Exhibit 99.1 to this 8-K filing.

No, the information furnished under Item 2.02 of this 8-K, including the press release, is specifically stated as 'shall not be deemed to be \"filed\" for purposes of the Securities Exchange Act of 1934, as amended.'

Investors should look for details on sales performance across different product segments (e.g., TAVR, TM T, Critical Care), reported earnings per share (EPS), any updates on strategic initiatives, clinical trial progress, and management's outlook or guidance for future periods.